This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Pre-IPO Raise Opportunity
Developing novel technologies to tackle antimicrobial resistance
SpectrumX is focused on bringing the world’s first patent protectable formulations of Hypochlorus Acid (HOCl) to the pharmaceutical and personal care market.
It’s first two product launches are a ground-breaking respiratory infection therapy for the treatment of the global virus, pneumonia, influenza, bronchitis and other upper and lower repiratory infections. Additionally the company is rolling out one of the most powerful hand sanitisers in the world with supplies to the NHS having already begun.
Both products utilise unique patent-pending Hydrochlorous Acid (HOCL) formulations. HOCl is a substance naturally produced in our bodies and released by our white blood cells when fighting infection.
Pre-IPO capital is currency being raised at a discount to an initial listing price on the London Stock Exchange, with a conservative estimated entry valuation of £50 million.
One of the most powerful hand sanitisers in the world - Spectricept™
Innovative respiratory therapy – SPC-069
WORLD'S FIRST and ONLY patent-protectable HOCL formulation
Benefits of early investment
To date in excess of £4 million has been invested by existing shareholders.
Pre-IPO capital is currently being raised via discounted Convertible Loan Notes.
SpectrumX have appointed Alfred Henry, one of the largest and leading advisory biotech firms for companies listing on the London Stock Exchange.
The prestigious Neville Registrars has been appointed as registrar and receiving agent for incoming investments and will hold funds until notes are issued.
Capital raised will be deployed to support the following key areas:
- Further supporting clinical trials
- Construction of MHRA compliant production facility in the North West
- Registration of products with both MHRA and EMA
- Expanding professional team
- Introduction of QMS (Quality Management System) for pharmaceutical manufacturing
- Testing unique HOCL for other potential medical applications
- Supporting launch products in UK and EU
London Stock Exchange
Target Listing Date
Est. Entry Valuation
Leading Corporate Advisory Firm
Prestigious Registrar & Receiving Agent
Take Advantage of This Pre-IPO Discount Now
Why HOCL?
Hypochlorous Acid (HOCL) is a naturally occurring substance that is biocompatible and safe for human use. It eradicates all bacteria, mycobacteria, spores, fungi, viruses – including the recent global virus.
Although it was discovered over a 100 years ago, developing a stabilised form of it outside the body has only been achieved in the past 20 years.
Our partner company, Spectrum Antimicrobials Inc. has known that HOCL is a product that will have a significant positive impact on the world, however traditional methods created an end-product with significant limitations.
Spectrum's team of scientists and microbiologists took this problem head on with the aim to solve it.
The outcome?
A completely unique production process that emulates how our bodies actually make HOCL, paving the way for a solution that truly harnesses our body's natural defence systems with "real world" resilience and fighting power.
The Impact of SpectrumX HOCL
“Globally there is a paradigm shift in the way people think about their health and wellbeing.
At SpectrumX we believe that we have harnessed the immense power of the human immune system with a product so versatile its applications are almost never ending.
As a company we want to play a part in this shift in society; from saving patients’ lives in hospitals, to providing consumers with innovative, safe and effective solutions for sanitisation and personal care.
With the combination of our world-renowned team, innovative developments and intellectual property, it is SpectrumX’s mission to be a globally leading HOCL health company, offering a better way to protect and improve people’s lives around the world.
– SpectrumX CEO, Damien Hancox
*Antimicrobial Resistance (AMR)
Current Global Death Rates
Deaths Attributed to AMR* by 2050
What the Medical Community is Saying About SpectrumX
“HOCL has been well researched, published and later cleared by FDA in different therapeutic areas including reduction of topical inflammation and topical pain as well as disinfection of food and food preparation areas. However, none of the above mentioned products have been able to provide stability at lower concentrations for safe use of the product on people. Spectrum Antimicrobials unique and patented formulations provide rapid disinfection in the presence of soil and other organic matter, at concentrations of 0.032% where other HOCL based products have been shown to certainly fail in stability and performance.”
– Dr. Jerry Stonemetz, Medical Director, Johns Hopkins University Hospital
– Dr. Jerry Stonemetz, Medical Director, Johns Hopkins University Hospital
“At the start of the pandemic, hand washing and hand sanitisers suddenly became even more important in the drive of preventing and limiting infection, but I don’t think we necessarily imagined we would be using sanitisers so intensively and for such a long period. Over time we have seen a really significant increase in skin conditions suffered by our staff from high usage of alcohol-based sanitisers. We proactively looked for a safe and effective solution to try to prevent this from happening and have now started utilising an HOCL based product produced by SpectrumX. Feedback from staff members has been overwhelmingly positive."
– Dr. Gary Davies, Medical Director, Chelsea & Westminister Hospital
– Dr. Gary Davies, Medical Director, Chelsea & Westminister Hospital
Take Advantage of This Pre-IPO Opportunity
SpectrumX is diversified across both healthcare and sanitisation.
We hold licenses for the only patent-protectable HOCL formulation – a naturally substance that historically has been problematic to reproduce.
Our focus is to bring groundbreaking respiratory therapy (SP-069) and to roll out one of the most powerful hand sanitisers in the world (Spectricept™) using our unique patent-pending HOCL formulation.
NO INVESTMENT OR MEDICAL ADVICE: The information and content provided on this site, or in any linked materials, is not intended to replace investment or medical advice nor is the information a substitute for professional expertise or treatment. If you have concerns, you should consult your investment advisor and/or your health care provider. The information on this page is the opinion of the Company, and is a paid advertisement.
Please see our Terms and Conditions for full details.